Curing blindness through regenerative cell therapies. We replace what is lost.
StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness.
We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.
The most innovative startup in health and life sciences in Europe at BioFit, 2020
Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023
Latest news
06/12/2023
Laura Koivusalo attends the Finnish Independence day reception
Our CEO and founder Laura Koivusalo celebrates the 106th Independence Day of Finland in the President's Castle. Recognized as a young innovator and leader in accordance with this year's theme "Changing times", Laura is honored to be invited to this most glamorous event of the year!
21/11/2023
New key hire - Dr Ross Macdonald joins as Chief Commercial Officer
We are excited to announce that Dr Ross Macdonald - former CEO of Cynata Therapeutics - joins our leadership team, bringing valuable commercial experience from the iPS cell therapy industry.
29/11/2023
Laura Koivusalo in expert panel at NLS Days in Copenhagen
Our CEO Laura Koivusalo gave insights from the trenches of cell therapy drug development in the "New Modalities" Super Session on the 1st day of Nordic Life Science days on Nov 29. On the panel, she joined representatives from the European Medicines Agency and the Canadian Centre for Regenerative Medicine.
05/09/2023
StemSight receives Business Finland Deep Tech Accelerator funding
Altogether 17 companies from different sectors were selected to Business Finland's new pilot funding program Deep Tech Accelerator. The total funding consists of two phases, the first of which is an EUR 400.000 grant and the second an EUR 1 million loan.
Supported by:
Co-funded by:
